Opus Point Partners Management
Latest statistics and disclosures from Opus Point Partners Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are IBB, Direxion Shs Etf Tr sp biotch bl, MTD, BMY, Seattle Genetics, and represent 53.26% of Opus Point Partners Management's stock portfolio.
- Added to shares of these 10 stocks: Fortress Biotech, UTHR, AMRN, ALKS, REGN, Direxion Shs Etf Tr sp biotch bl, FGEN, LGND, EXEL, ALNY.
- Started 2 new stock positions in UTHR, ALKS.
- Reduced shares in these 10 stocks: Immunomedics, SRPT, BLUE, INSM, PCRX, , VKTX, MDGL, ANAB, AGIO.
- Sold out of its positions in AGIO, FOLD, ANAB, BLUE, Immunomedics, INSM, MDGL, PCRX, SRPT, VKTX.
- Opus Point Partners Management was a net seller of stock by $-3.9M.
- Opus Point Partners Management has $55M in assets under management (AUM), dropping by -18.13%.
- Central Index Key (CIK): 0001600175
Tip: Access up to 7 years of quarterly data
Positions held by Opus Point Partners Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Opus Point Partners Management
Opus Point Partners Management holds 54 positions in its portfolio as reported in the September 2019 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| iShares NASDAQ Biotechnology Index (IBB) | 37.8 | $21M | 210k | 99.51 |
|
|
| Direxion Shs Etf Tr sp biotch bl | 5.6 | $3.1M | 100k | 30.90 |
|
|
| Mettler-Toledo International (MTD) | 4.1 | $2.3M | 3.2k | 704.48 |
|
|
| Bristol Myers Squibb (BMY) | 3.0 | $1.7M | 33k | 50.70 |
|
|
| Seattle Genetics | 2.8 | $1.5M | 18k | 85.41 |
|
|
| Illumina (ILMN) | 2.6 | $1.4M | 4.7k | 304.17 |
|
|
| Vertex Pharmaceuticals Incorporated (VRTX) | 2.5 | $1.4M | 8.3k | 169.46 |
|
|
| Ionis Pharmaceuticals (IONS) | 2.2 | $1.2M | 20k | 59.93 |
|
|
| Alnylam Pharmaceuticals (ALNY) | 2.0 | $1.1M | +2% | 14k | 80.39 |
|
| Alexion Pharmaceuticals | 1.8 | $973k | 9.9k | 97.96 |
|
|
| Qiagen Nv | 1.7 | $951k | 29k | 32.95 |
|
|
| Spark Therapeutics | 1.7 | $941k | 9.7k | 97.02 |
|
|
| Fortress Biotech | 1.6 | $865k | +162% | 614k | 1.41 |
|
| Proqr Thrapeutics N V shs euro (PRQR) | 1.4 | $798k | 139k | 5.76 |
|
|
| Incyte Corporation (INCY) | 1.4 | $791k | 11k | 74.21 |
|
|
| EXACT Sciences Corporation (EXAS) | 1.4 | $771k | 8.5k | 90.34 |
|
|
| Regeneron Pharmaceuticals (REGN) | 1.2 | $677k | +9% | 2.4k | 277.57 |
|
| BioMarin Pharmaceutical (BMRN) | 1.2 | $654k | +3% | 9.7k | 67.42 |
|
| Deciphera Pharmaceuticals (DCPH) | 1.1 | $632k | 19k | 33.92 |
|
|
| Ascendis Pharma A S (ASND) | 1.1 | $596k | 6.2k | 96.28 |
|
|
| Celgene Corporation | 1.0 | $559k | 5.6k | 99.38 |
|
|
| Uniqure Nv (QURE) | 1.0 | $560k | 14k | 39.40 |
|
|
| Crispr Therapeutics (CRSP) | 1.0 | $542k | 13k | 41.02 |
|
|
| Epizyme | 0.9 | $520k | 50k | 10.32 |
|
|
| Amarin Corporation (AMRN) | 0.9 | $510k | +102% | 34k | 15.16 |
|
| Blueprint Medicines (BPMC) | 0.9 | $498k | 6.8k | 73.45 |
|
|
| Audentes Therapeutics | 0.9 | $487k | 17k | 28.09 |
|
|
| G1 Therapeutics (GTHX) | 0.9 | $475k | 21k | 22.79 |
|
|
| Global Blood Therapeutics In | 0.8 | $460k | 9.5k | 48.53 |
|
|
| Biohaven Pharmaceutical Holding | 0.8 | $453k | 11k | 41.74 |
|
|
| Arena Pharmaceuticals | 0.8 | $447k | 9.8k | 45.75 |
|
|
| ACADIA Pharmaceuticals (ACAD) | 0.8 | $432k | 12k | 35.99 |
|
|
| Gw Pharmaceuticals Plc ads | 0.8 | $423k | 3.7k | 115.13 |
|
|
| Zogenix | 0.7 | $389k | 9.7k | 40.00 |
|
|
| Macrogenics (MGNX) | 0.7 | $384k | 30k | 12.77 |
|
|
| Intellia Therapeutics (NTLA) | 0.7 | $380k | 29k | 13.34 |
|
|
| Bio-techne Corporation (TECH) | 0.6 | $303k | 1.6k | 195.36 |
|
|
| Iqvia Holdings (IQV) | 0.5 | $297k | 2.0k | 149.62 |
|
|
| Amgen (AMGN) | 0.5 | $294k | +8% | 1.5k | 193.68 |
|
| Charles River Laboratories (CRL) | 0.5 | $280k | 2.1k | 132.58 |
|
|
| Neurocrine Biosciences (NBIX) | 0.5 | $282k | +3% | 3.1k | 90.18 |
|
| Checkpoint Therapeutics | 0.5 | $281k | 113k | 2.49 |
|
|
| United Therapeutics Corporation (UTHR) | 0.5 | $279k | NEW | 3.5k | 79.76 |
|
| Grifols S A Sponsored Adr R (GRFS) | 0.5 | $264k | 13k | 20.01 |
|
|
| Biogen Idec (BIIB) | 0.5 | $261k | 1.1k | 232.41 |
|
|
| Gilead Sciences (GILD) | 0.5 | $259k | 4.1k | 63.45 |
|
|
| Intercept Pharmaceuticals In | 0.5 | $261k | -33% | 3.9k | 66.48 |
|
| Ligand Pharmaceuticals In (LGND) | 0.4 | $242k | +15% | 2.4k | 99.67 |
|
| Exelixis (EXEL) | 0.4 | $232k | +14% | 13k | 17.67 |
|
| Nektar Therapeutics (NKTR) | 0.4 | $235k | +3% | 13k | 18.18 |
|
| Alkermes (ALKS) | 0.4 | $227k | NEW | 12k | 19.52 |
|
| Ultragenyx Pharmaceutical (RARE) | 0.4 | $217k | 5.1k | 42.85 |
|
|
| Fibrogen (FGEN) | 0.4 | $212k | +17% | 5.7k | 36.92 |
|
| Recro Pharma (SCTL) | 0.2 | $126k | 11k | 11.10 |
|
Past Filings by Opus Point Partners Management
SEC 13F filings are viewable for Opus Point Partners Management going back to 2014
- Opus Point Partners Management 2019 Q3 filed Nov. 14, 2019
- Opus Point Partners Management 2019 Q2 filed Aug. 14, 2019
- Opus Point Partners Management 2019 Q1 filed May 15, 2019
- Opus Point Partners Management 2018 Q4 filed Feb. 14, 2019
- Opus Point Partners Management 2018 Q3 filed Nov. 14, 2018
- Opus Point Partners Management 2018 Q2 filed Aug. 14, 2018
- Opus Point Partners Management 2018 Q1 filed May 15, 2018
- Opus Point Partners Management 2017 Q4 filed Feb. 14, 2018
- Opus Point Partners Management 2017 Q2 amended filed Nov. 17, 2017
- Opus Point Partners Management 2017 Q3 filed Nov. 14, 2017
- Opus Point Partners Management 2017 Q2 filed Aug. 14, 2017
- Opus Point Partners Management 2017 Q1 filed May 15, 2017
- Opus Point Partners Management 2016 Q4 filed Feb. 14, 2017
- Opus Point Partners Management 2016 Q3 filed Nov. 14, 2016
- Opus Point Partners Management 2016 Q2 filed Aug. 15, 2016
- Opus Point Partners Management 2016 Q1 restated filed May 16, 2016